Entasis’s Isaacs to Retire, Altarac Appointed Chief Medical Officer

David Altarac has been appointed chief medical officer of Entasis Therapeutics (NASDAQ: [[ticker:ETTX]]). He will succeed Robin Isaacs, who will retire from the Waltham, MA-based company at the end of the year. Entasis said Isaacs will continue to serve as an advisor. Altarac’s experience includes senior roles at Shire, NeoStem, and Merck (NYSE: [[ticker:MRK]]). Entasis, an AstraZeneca (NYSE: [[ticker:AZN]]) spinout, is developing antibacterial products for infections caused by drug-resistant bacteria.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.